Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 22;37(3):529–538. doi: 10.1038/s41375-022-01799-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A Oncoplot showing the distribution of clinical features and genetic abnormalities within the PAX5alt subtype and associated copy number profile risk status (UKALL-CNA [36] and IKZF1_plus [40]). Coexistence of CRLF2-r is indicated in red in the B-other-ALL subtype row. Copy number profile status was unavailable for patients lacking Multiplex Ligation-dependent Probe Amplification (MLPA) data. *The SALSA P335-ALL-IKZF1 and P327-iAMP21-ERG MLPA kits were used to determine gene copy number. Relapses were defined as follows: very early, < 18 months from diagnosis; early, within 6 months of end of treatment; late >6 months after end of treatment. B Circos plot illustrating the range of PAX5 translocation partner genes in PAX5-r. C Stacked bar plot showing the distribution of PAX5alt abnormalities amongst different age groups. NCI National Cancer Institute, WBC White blood cell count, MRD Minimal residual disease, t-NGS Targeted next-generation sequencing, WGS Whole genome sequencing, PAX5-r PAX5 rearranged, PAX5-ITD PAX5 internal tandem duplication, CNA Copy number alteration.